TXMD · Therapeuticsmd, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $1.76M | $69.96M | $69.96M | $86.95M | $64.87M |
| Cost of Revenue | - | - | - | $1.40M | $18.84M | $15.97M |
| Gross Profit | - | - | $1.30M | $68.57M | $68.11M | $48.90M |
| R&D | - | - | - | - | $7.09M | $10.43M |
| SG&A | $6.10M | $4.74M | $8.90M | $57.90M | $76.95M | $192.96M |
| Total Operating Expenses | $7.41M | $6.52M | $9.82M | $67.38M | $207.88M | $204.44M |
| D&A | $384.0K | $509.0K | $922.0K | $1.19M | $4.09M | $1.04M |
| Operating Income | ($4.39M) | ($4.76M) | ($8.52M) | $1.19M | ($139.77M) | ($155.54M) |
| Interest Expense | $8.0K | $9.5K | $300.0K | $36.06M | $32.92M | $28.58M |
| Income Tax | - | ($31.0K) | ($43.0K) | - | - | - |
| Net Income | ($569.0K) | ($2.18M) | ($10.28M) | $112.00M | ($172.41M) | ($183.52M) |
| EPS - Basic | ($0.05) | ($0.19) | ($0.98) | $12.41 | - | - |
| EPS - Diluted | ($0.05) | ($0.19) | ($0.98) | ($21.66) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.48M | $4.33M | $4.33M | $64.91M | $65.12M | $80.49M |
| Accounts Receivable | - | - | - | - | $36.18M | $32.38M |
| Inventory | - | - | - | - | $7.62M | $7.99M |
| Accounts Payable | $377.0K | $258.0K | $27.0K | $2.16M | $20.32M | $21.07M |
| Current Assets | $14.45M | $12.26M | $11.80M | $55.35M | $119.47M | $128.40M |
| Total Assets | $37.66M | $38.82M | $43.31M | $90.46M | $169.47M | $181.61M |
| Current Liabilities | $4.79M | $5.17M | $6.85M | $46.84M | $252.89M | $59.24M |
| Long-term Debt | - | - | - | - | $0 | $237.70M |
| Total Liabilities | $10.78M | $11.45M | $14.02M | $55.31M | $263.09M | $305.61M |
| Stockholders' Equity | $26.88M | $27.37M | $29.29M | $35.14M | ($93.62M) | ($124.00M) |
| Retained Earnings | ($952.39M) | ($951.82M) | ($949.64M) | ($939.36M) | ($1.05B) | ($878.95M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.45M | $1.17M | ($23.08M) | ($55.13M) | ($142.69M) | ($159.47M) |
| Investing Cash Flow | - | - | - | ($2.22M) | ($2.22M) | ($1.60M) |
| Financing Cash Flow | - | $3.15M | $3.15M | $129.55M | $129.55M | $80.72M |
| CapEx | - | - | - | - | $34.0K | $207.1K |
| Free Cash Flow | - | - | - | - | ($142.73M) | ($159.68M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 1.9% | 98.0% | 78.3% | 75.4% |
| Operating margin | - | -270.3% | -12.2% | 1.7% | -160.7% | -239.8% |
| EBITDA margin | - | -241.4% | -10.9% | 3.4% | -156.0% | -238.2% |
| Net margin | - | -123.9% | -14.7% | 160.1% | -198.3% | -282.9% |
| Free cash flow margin | - | - | - | - | -164.1% | -246.1% |
| FCF / Net income | - | - | - | - | 0.83 | 0.87 |
| R&D / Revenue | - | - | - | - | 8.1% | 16.1% |
| SG&A / Revenue | - | 269.4% | 12.7% | 82.8% | 88.5% | 297.5% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -1.5% | -5.6% | -23.7% | 123.8% | -101.7% | -101.1% |
| Return on equity | -2.1% | -8.0% | -35.1% | 318.7% | 184.2% | 148.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.02 | 2.37 | 1.72 | 1.18 | 0.47 | 2.17 |
| Quick ratio | 3.02 | 2.37 | 1.72 | 1.18 | 0.44 | 2.03 |
| Cash ratio | 1.56 | 0.84 | 0.63 | 1.39 | 0.26 | 1.36 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | 0.00 | -1.92 |
| Debt / Assets | - | - | - | - | 0.00 | 1.31 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -548.8x | -501.1x | -28.4x | 0.0x | -4.2x | -5.4x |
| Equity multiplier | 1.40 | 1.42 | 1.48 | 2.57 | -1.81 | -1.46 |
| Liabilities / Assets | 0.29 | 0.29 | 0.32 | 0.61 | 1.55 | 1.68 |
| Efficiency | ||||||
| Asset turnover | - | 0.05 | 1.62 | 0.77 | 0.51 | 0.36 |
| Inventory turnover | - | - | - | - | 2.47 | 2.00 |
| Days sales outstanding | - | - | - | - | 152d | 182d |
| Days inventory outstanding | - | - | - | - | 148d | 183d |
| Days payable outstanding | - | - | - | 565d | 394d | 481d |
| Cash conversion cycle | - | - | - | - | -94d | -117d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.7x | 0.0x | 0.8x | 1.3x | - | - |
| P / S | - | 0.0x | 0.3x | 0.6x | - | - |
| EV / EBITDA | - | - | - | -8.6x | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | -97.5% | 0.0% | -19.5% | 34.0% | 30.7% |
| Revenue CAGR (3y) | - | -72.7% | 2.6% | 12.1% | 65.0% | 49.7% |
| Revenue CAGR (5y) | - | -48.7% | 29.3% | 29.3% | 42.1% | 49.2% |
| Gross profit growth (YoY) | - | - | -98.1% | 0.7% | 39.3% | 12.9% |
| Operating income growth (YoY) | 7.8% | 44.2% | - | - | 10.1% | -2.9% |
| Net income growth (YoY) | 73.9% | 78.8% | - | - | 6.1% | -4.2% |
| EPS growth (YoY) | 73.7% | 80.6% | 95.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 10.6% | 5.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -1.8% | -6.5% | -16.7% | - | 24.5% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$1.30M totalLicense$1.30M · 100.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TherapeuticsMD against the 5 most active filers in the same SIC group.